Journal
NATURE BIOTECHNOLOGY
Volume 34, Issue 8, Pages 869-+Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nbt.3620
Keywords
-
Categories
Funding
- National Institutes of Health (NIH) Director's Pioneer Award [DP1 GM105378]
- NIH [R01 GM107427]
- Jim and Ann Orr Research Scholar Award
- Natural Sciences and Engineering Research Council of Canada Postdoctoral Fellowship
- Massachusetts General Hospital Collaborative Center for X-Linked Dystonia-Parkinsonism
- MGH Tosteson Award
Ask authors/readers for more resources
The activities and genome-wide specificities of CRISPR-Cas Cpf1 nucleases(1) are not well defined. We show that two Cpf1 nucleases from Acidaminococcus sp. BV3L6 and Lachnospiraceae bacterium ND2006 (AsCpf1 and LbCpf1, respectively) have on-target efficiencies in human cells comparable with those of the widely used Streptococcus pyogenes Cas9 (SpCas9)(2-5). We also report that four to six bases at the 3' end of the short CRISPR RNA (crRNA) used to program Cpf1 nucleases are insensitive to single base mismatches, but that many of the other bases in this region of the crRNA are highly sensitive to single or double substitutions. Using GUIDE-seq and targeted deep sequencing analyses performed with both Cpf1 nucleases, we were unable to detect off-target cleavage for more than half of 20 different crRNAs. Our results suggest that AsCpf1 and LbCpf1 are highly specific in human cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available